Use of bortezomib in heavy-chain deposition disease: A report of 3 cases

American Journal of Kidney Diseases

Volumn 64, Issue 1, 2014, Pages 123-127

  Patel, Kinjal ^a   Dillon, John J ^b   Leung, Nelson ^b   Bomback, Andrew S ^a   Appel, Gerald B ^a   D'Agati, Vivette ^a   Canetta, Pietro A ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b MAYO CLINIC   (United States)

Author keywords

bortezomib; Heavy chain deposition disease; Index Words; monoclonal immunoglobulin deposition disease; nephrotic syndrome

Indexed keywords

AMLODIPINE; ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; BORTEZOMIB; CLONIDINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIURETIC AGENT; GABAPENTIN; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; LENALIDOMIDE; PRAVASTATIN; RITUXIMAB;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD VESSEL WALL; BONE MARROW BIOPSY; CASE REPORT; CLINICAL EFFECTIVENESS; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG USE; EDEMA; ERYTHROCYTE TRANSFUSION; ESOPHAGOGASTRODUODENOSCOPY; FIBROSING ALVEOLITIS; FOOT NEUROPATHY; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HAND NEUROPATHY; HEAVY CHAIN DEPOSITION DISEASE; HEMATOLOGIST; HEMATURIA; HISPANIC; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TUBULE BASEMENT MEMBRANE; LABORATORY TEST; MALE; MEDICAL HISTORY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PARAPROTEINEMIA; PELVIS RADIOGRAPHY; PERIPHERAL NEUROPATHY; PROTEINURIA; REMISSION; SLEEP DISORDERED BREATHING; STAINING; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY; TREATMENT DURATION; URINALYSIS;

BORTEZOMIB; HEAVY-CHAIN DEPOSITION DISEASE; MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE; NEPHROTIC SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; GLOMERULAR FILTRATION RATE; HEAVY CHAIN DISEASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KIDNEY; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 84903128195     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.01.425     Document Type: Article

References (13)

1. J. Buxbaum, and G. Gallo Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases Hematol Oncol Clin North Am 13 6 1999 1235 1248
2. G. Gallo, M. Picken, J. Buxbaum, and B. Frangione The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias Semin Hematol 26 3 1989 234 245
3. P. Aucouturier, A.A. Khamlichi, and G. Touchard et al. Brief report: heavy-chain deposition disease N Engl J Med 329 19 1993 1389 1393
4. J. Soma, K. Sato, and T. Sakuma et al. Immunoglobulin gamma3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia Am J Kidney Dis 43 1 2004 E10 E16
5. M.P. Alexander, S.H. Nasr, D.C. Watson, G.P. Mendez, and H.G. Rennke Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature Am J Kidney Dis 58 4 2011 621 625
6. N. Kambham, G.S. Markowitz, G.B. Appel, M.J. Kleiner, P. Aucouturier, and V. D'Agati Heavy chain deposition disease: the disease spectrum Am J Kidney Dis 33 5 1999 954 962
7. J. Lin, G.S. Markowitz, and A.M. Valeri et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum J Am Soc Nephrol 12 7 2001 1482 1492
8. R. Masai, H. Wakui, and M. Togashi et al. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease Clin Nephrol 71 1 2009 9 20
9. S.H. Nasr, A.M. Valeri, and L.D. Cornell et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution Clin J Am Soc Nephrol 7 2 2012 231 239
10. Y. Oe, I. Nakaya, M. Yahata, T. Sakuma, H. Sato, and J. Soma A case of gamma1-heavy chain deposition disease successfully treated with melphalan and prednisolone therapy Intern Med 49 14 2010 1411 1415
11. P. Moreau The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies Semin Hematol 49 suppl 1 2012 S33 S46
12. P.G. Richardson, M. Delforge, and M. Beksac et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma Leukemia 26 4 2012 595 608
13. P.G. Richardson, W. Xie, and C. Mitsiades et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy J Clin Oncol 27 21 2009 3518 3525